Decompression SicknessPhase 1NASA PrebreathNCT06740305
NASA Prebreathe Study
A Phase 1 study testing Altitude and 100% Oxygen in people with Decompression Sickness, run by Duke University at 1 site in United States.
Trial summary
This study will validate the experimental method and chamber facility at the Duke Center for Hyperbaric Medicine \& Environmental Physiology and test team capabilities to support NASA decompression sickness (DCS) studies. Read more about this study
- Who is it for?
- Ages 18 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Decompression Sickness
- What is being tested?
- Altitude and 100% Oxygen
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 19 participants
- Where
- 1 siteUnited States
- Study dates
- 5 May 2025to 21 Aug 2025
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Non-smokers
- VO2pk >35 ml/kg/min (males)
- VO2pk >30 ml/kg/min (females)
Who cannot join
- Pregnancy
- Lung and heart disease
- Hypertension
- Diabetes
- Musculoskeletal pain conditions
- Need for regular medications such as analgesics
Trial locations and contacts
1 site in 1 country.
United States1 site
Duke University Medical Center
Durham, North Carolina, 27710
About this study
This study will validate the experimental method and chamber facility at the Duke Center for Hyperbaric Medicine \& Environmental Physiology and test team capabilities to support NASA decompression sickness (DCS) studies. This project is related to development of protocols for extravehicular activity (EVA, "spacewalks") to minimize the risk of decompression sickness. Duke will perform four test days, collecting and recording data each day. Each test day will involve 3 volunteer subjects ages 18-50 years, who will breathe 100% oxygen for 6 hours. This will be followed by 6 hours in the hypobaric chamber at 1/3 atmosphere, during which subjects will perform various tasks, including arm and leg exercises, and undergo ultrasound testing to detect vascular bubbles. End-points will include bubble scores, and decompression sickness (DCS). If subjects develop DCS symptoms they will immediately be recompressed to ambient pressure and be assessed and treated.
Read the detailed description
Applicants will be screened to provide at least 3 subjects plus one test operator (Doppler /ultrasound technician) per day to participate in four 12-hour chamber runs for this pilot testing. Screening back-up subjects in case of subject availability issues, withdrawal, or disqualification will be included. Subjects will be screened per standard protocols, and the subject pool will include females to demonstrate their capabilities to recruit and test this important population. NASA will provide inclusion and exclusion criteria for a population demographic similar to the astronaut corps. Following a screening process, subjects will participate in a familiarization session during which they will receive verbal and written description of the test protocol, be encouraged to ask questions, and will provide written informed consent before proceeding to participation. Thereafter, subjects will be familiarized with the chamber protocol and safety procedures. Subjects also will be familiarized with the EVA simulation workstations, and metabolic rate will be measured while performing the arm ergometry and stepping exercises at several low work rates (submaximal exercise intensity) to verify the cadence or work rates required for the in-chamber exercise prescription.
A test plan will be implemented that includes a 6-hour prebreathe of 100% oxygen using a transparent hyperbaric hood, followed by a simulation of EVA lasting 6 hours, or until signs and symptoms that require test termination (per NASA and Duke standards), test termination by subject request, or facility or monitoring capabilities malfunctions. These sessions will include successful mask operations and demonstration of safety procedures. An additional 30 minutes will be allotted for re-pressurization and post-test monitoring.
Appropriate medical support will be provided to perform pre-chamber physical examination before ingress, during the protocol, for treatment and management of subjects as needed, clearance of subjects after the protocol is completed, and follow-up in the days after the chamber run, as required. Responsibilities of the medical personnel include monitoring and interpretation of 2-D ultrasound and Doppler as well as monitoring of the subject's self-report and symptoms of DCS or intolerance. Prebreathe Conditions The Duke Center for Hyperbaric Medicine \& Environmental Physiology will demonstrate the capability to perform 100% O2 prebreathe durations up to 6 hours. Subjects will begin O2 breathing at the start of the prebreathe and continue breathing 100% O2 through decompression and until re-pressurization is completed. Subjects will be provided fluids ad libitum without a break in prebreathe (using drink port). NASA will provide the breathing masks and/or design for their construction or provide approval for a suitable substitution. Food will be allowed prior to start of mask prebreathe but not during the test protocol (for 12 hours). Subjects also are not allowed to sleep during the test protocol. EVA Simulation Duke will demonstrate their capacity to perform a simulated 6-hour EVA and maintain standardized monitoring practices. To simulate the suit environment, the chamber will depress to 4.3 psia (0.3 ATA, approximately 30,000 ft altitude) before initiating the EVA simulation tasks described below. The start time of the EVA is defined by the arrival at the desired level of decompression, and the end time of the EVA is defined by the start of re-pressurization. EVA simulation will include rotation of each subject through a repetitive series of tasks at predetermined intervals in a pre-determined order using a NASA-defined or provided workstations. The EVA is simulated using eight stations, nominally performed in 2 cycles of 4 stations, with subjects rotating between stations every 5 minutes. In one cycle, subjects will rotate through stations that simulate ambulation (low step), upper body technical tasks (standing board), and load carrying (weight transfer), and 2-D ultrasound while subjects are supine on a cot. In the other cycle, subjects will rotate through stations that simulate more vigorous ambulation (high step), upper body physical exertion (arm ergometry), technical tasks performed in a kneeling position (kneeling board), and Doppler ultrasound while supine. Thus, in each cycle subjects will perform 15 minutes of low- to moderate-intensity exercise followed by 5 minutes of monitoring and rest. Work rates during arm ergometry (cadence and resistance) and stepping (cadence) will be prescribed based upon the results of the VO2pk test and the pre-test EVA simulation familiarization with metabolic gas analysis. During ultrasound imaging and Doppler waveform acquisition, at least 10 cardiac cycles will be monitored and recorded in each of three conditions in sequential order: rest, flexing/bending of the arms and legs, and rest. Compliance of the subjects with the prescribed procedures should be documented, including the time at each station, work rates (cadence and load), symptoms reported by the subjects, and test operator observations.
A standardized set of measurements will be used to monitor and document test subjects during the prebreathe, decompression, and recompression. Test operators will record all symptoms reported by the test subjects throughout the duration of the protocol, whether in response to prompting by the test operators or spontaneous self-reporting. Subjects will be removed from the chamber and repressurized (airlock or chamber) at the onset of DCS (Type I or Type II). NASA defines DCS severity with the following criteria: Mild DCS (Type I), Uncomplicated: Symptoms involving joint pain, peripheral nervous system, or simple skin bends that resolve upon repress or within the first 20 minutes of treatment. Mild DCS (Type I), Complicated: Symptoms involving joint pain, peripheral nervous system, or simple skin bends that DO NOT resolve upon repress or within the first 20 minutes of treatment. Mild DCS (Type I) - Repetitive: Mild DCS symptoms involving joint pain, peripheral nervous system, or simple skin bends that occur after a successful treatment and within 30 days of a prior case of DCS for ground-based exposure. These are considered discrete occurrences of DCS in response to chronologically discrete exposures. Serious DCS (Type II): Symptoms involving the Central Nervous System (CNS), cardiovascular system (circulatory collapse/shock), pulmonary system (chokes).
Test operators will query subjects for responses to standardized questionnaires during each rotation through the resting/ultrasound station. Subjects will report a rating of perceived exertion (RPE) and pain using NASA-defined scales at the end of each exercise bout (i.e., after 5 minutes of arm ergometry, stepping).
2-D imaging and Doppler ultrasound for detection of venous gas emboli will be performed by a qualified test operator during each rotation through the resting/ultrasound station while the subject is at rest and following exercise. Doppler and 2-D ultrasound will be recorded and stored electronically with relevant metadata (e.g., subject ID) for post-exposure review and analysis. Doppler results will be scored using the Spencer coding convention and ultrasound will be scored using the Eftedal-Brubbak (EB) scale (0-7).
Heart rate will be continuously monitored and recorded from which data can be downloaded and stored electronically for post-exposure analysis. Test operators will be able to observe the current heart rate from the device as needed and will manually record heart rate at the end of each 5-minute rotation through the EVA simulation stations.
Oxygen saturation (SpO2) will be monitored and recorded continuously during the prebreathe, decompression, and recompression using a device from which the data can be downloaded and stored electronically for post-exposure analysis. Test operators must be able to observe the current SpO2 from the device as needed and will manually record SpO2 at the end of each 5-minute rotation through the EVA simulation stations.
At the conclusion of each test day, Duke will deliver electronic records to NASA using a secure, NASA approved method. The data package will include subject metadata, console and/or operator's logs (including chamber event time, prebreathe records, EVA time, EVA station schedule), chamber pressure recordings (demonstrating depress and repress rates as well as sustained chamber pressure), chamber environmental conditions (partial pressures of O2, CO2, and N2, temperature, humidity), questionnaires, medical monitoring logs, heart rate and pulse oximetry records (if recorded), Doppler and ultrasound recordings, in-chamber video of EVA workstations, and DCS case descriptions. Doppler and ultrasound images will be scored by 3 reviewers in a blinded fashion.
- Conditions
- Decompression Sickness
- Being tested
- Altitude, 100% Oxygen
- Keywords
- Space, Microgravity, Decompression, Decompression sickness, Altitude
- Medical subject headings
- Decompression Sickness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AltitudeOther
Subjects will be exposed to simulated altitude (30,000 ft, 4.3 psia) in a hypobaric chamber. This is the same ambient pressure to which astronauts are exposed during EVA ("space walks").
100% OxygenDrug
Oxygen pre-breathing prior to altitude or simulated high altitude exposure is routinely used by the Air Force, NASA and organizations such as Duke Medical Center to prevent and treat decompression sickness as well as for treatment of patients. Oxygen used for this study is medical grade.
| Study group | Role | What they receive |
|---|---|---|
| Healthy Volunteers | Experimental | Each participant in this group will be exposed to simulated altitude. Receives: Other: Altitude; Drug: 100% Oxygen |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with each type of decompression sickness
Mild DCS (Type I), Uncomplicated: Symptoms involving joint pain, peripheral nervous system, or simple skin bends that resolve upon repress or within the first 20 minutes of treatment.
Mild DCS (Type I), Complicated: Symptoms involving joint pain, peripheral nervous system, or simple skin bends that DO NOT resolve upon repress or within the first 20 minutes of treatment.
Mild DCS (Type I) - Repetitive: Mild DCS symptoms involving joint pain, peripheral nervous system, or simple skin bends that occur after a successful treatment and within 30 days of a prior case of DCS for ground-based exposure. These are considered discrete occurrences of DCS in response to chronologically discrete exposures.
Serious DCS (Type II): Symptoms involving the Central Nervous System (CNS), cardiovascular system (circulatory collapse/shock), pulmonary system (chokes).
Measured: 24 hours
Secondary outcomes (1)
Number of participants with venous gas embolism
Ultrasound will be used to detect circulating bubbles
Measured: 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Dec 2024
- Study start5 May 2025
- Primary completion21 Aug 2025
- Study completion21 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Decompression SicknessStudies of the same condition, open and under way.
- More trials run by Duke UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 19 participants (actual)
Sponsor and investigators
- Lead sponsor
- Duke University
- Sponsor type
- University, hospital or other
- Collaborators
- National Aeronautics and Space Administration (NASA)
- Responsible party
- Sponsor
- Investigators
- Richard E Moon, MD, Principal investigator, Duke University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06740305
- Sponsor's protocol ID
- Pro00116846
- Other IDs
- 80NSSC24PB887
- Acronym
- NASA Prebreath
- Status last verified
- May 2026
- First submitted
- 19 Nov 2024
- Last updated
- 1 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Mollerlokken A, Blogg SL, Doolette DJ, Nishi RY, Pollock NW. Consensus guidelines for the use of ultrasound for diving research. Diving Hyperb Med. 2016 Mar;46(1):26-32.
PubMed 27044459Le DQ, Dayton PA, Tillmans F, Freiberger JJ, Moon RE, Denoble P, Papadopoulou V. Ultrasound in decompression research: fundamentals, considerations, and future technologies. Undersea Hyperb Med. 2021 First Quarter;48(1):59-72. doi: 10.22462/01.03.2021.8.
PubMed 33648035
Study at a glance
From the registry record, last updated by the sponsor on 1 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- NASA Prebreathe Study
- ClinicalTrials.gov ID
- NCT06740305
- Acronym / sponsor ID
- NASA Prebreath / Pro00116846
- Conditions
- Decompression Sickness
- Keywords
- Space, Microgravity, Decompression, Decompression sickness, Altitude
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 19 participants (actual)
- Lead sponsor
- Duke UniversityUniversity, hospital or other
- Collaborators
- National Aeronautics and Space Administration (NASA)
- Study start
- 5 May 2025 (actual)
- Primary completion
- 21 Aug 2025 (actual)
- Study completion
- 21 Aug 2025 (actual)
- First posted
- 18 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will validate the experimental method and chamber facility at the Duke Center for Hyperbaric Medicine \& Environmental Physiology and test team capabilities to support NASA decompression sickness (DCS) studies. This project is related to development of protocols for extravehicular activity (EVA, "spacewalks") to minimize the risk of decompression sickness. Duke will perform four test days, collecting and recording data each day. Each test day will involve 3 volunteer subjects ages 18-50 years, who will breathe 100% oxygen for 6 hours. This will be followed by 6 hours in the hypobaric chamber at 1/3 atmosphere, during which subjects will perform various tasks, including arm and leg exercises, and undergo ultrasound testing to detect vascular bubbles. End-points will include bubble scores, and decompression sickness (DCS). If subjects develop DCS symptoms they will immediately be recompressed to ambient pressure and be assessed and treated.
Detailed description
Applicants will be screened to provide at least 3 subjects plus one test operator (Doppler /ultrasound technician) per day to participate in four 12-hour chamber runs for this pilot testing. Screening back-up subjects in case of subject availability issues, withdrawal, or disqualification will be included. Subjects will be screened per standard protocols, and the subject pool will include females to demonstrate their capabilities to recruit and test this important population. NASA will provide inclusion and exclusion criteria for a population demographic similar to the astronaut corps. Following a screening process, subjects will participate in a familiarization session during which they will receive verbal and written description of the test protocol, be encouraged to ask questions, and will provide written informed consent before proceeding to participation. Thereafter, subjects will be familiarized with the chamber protocol and safety procedures. Subjects also will be familiarized with the EVA simulation workstations, and metabolic rate will be measured while performing the arm ergometry and stepping exercises at several low work rates (submaximal exercise intensity) to verify the cadence or work rates required for the in-chamber exercise prescription.
A test plan will be implemented that includes a 6-hour prebreathe of 100% oxygen using a transparent hyperbaric hood, followed by a simulation of EVA lasting 6 hours, or until signs and symptoms that require test termination (per NASA and Duke standards), test termination by subject request, or facility or monitoring capabilities malfunctions. These sessions will include successful mask operations and demonstration of safety procedures. An additional 30 minutes will be allotted for re-pressurization and post-test monitoring.
Appropriate medical support will be provided to perform pre-chamber physical examination before ingress, during the protocol, for treatment and management of subjects as needed, clearance of subjects after the protocol is completed, and follow-up in the days after the chamber run, as required. Responsibilities of the medical personnel include monitoring and interpretation of 2-D ultrasound and Doppler as well as monitoring of the subject's self-report and symptoms of DCS or intolerance. Prebreathe Conditions The Duke Center for Hyperbaric Medicine \& Environmental Physiology will demonstrate the capability to perform 100% O2 prebreathe durations up to 6 hours. Subjects will begin O2 breathing at the start of the prebreathe and continue breathing 100% O2 through decompression and until re-pressurization is completed. Subjects will be provided fluids ad libitum without a break in prebreathe (using drink port). NASA will provide the breathing masks and/or design for their construction or provide approval for a suitable substitution. Food will be allowed prior to start of mask prebreathe but not during the test protocol (for 12 hours). Subjects also are not allowed to sleep during the test protocol. EVA Simulation Duke will demonstrate their capacity to perform a simulated 6-hour EVA and maintain standardized monitoring practices. To simulate the suit environment, the chamber will depress to 4.3 psia (0.3 ATA, approximately 30,000 ft altitude) before initiating the EVA simulation tasks described below. The start time of the EVA is defined by the arrival at the desired level of decompression, and the end time of the EVA is defined by the start of re-pressurization. EVA simulation will include rotation of each subject through a repetitive series of tasks at predetermined intervals in a pre-determined order using a NASA-defined or provided workstations. The EVA is simulated using eight stations, nominally performed in 2 cycles of 4 stations, with subjects rotating between stations every 5 minutes. In one cycle, subjects will rotate through stations that simulate ambulation (low step), upper body technical tasks (standing board), and load carrying (weight transfer), and 2-D ultrasound while subjects are supine on a cot. In the other cycle, subjects will rotate through stations that simulate more vigorous ambulation (high step), upper body physical exertion (arm ergometry), technical tasks performed in a kneeling position (kneeling board), and Doppler ultrasound while supine. Thus, in each cycle subjects will perform 15 minutes of low- to moderate-intensity exercise followed by 5 minutes of monitoring and rest. Work rates during arm ergometry (cadence and resistance) and stepping (cadence) will be prescribed based upon the results of the VO2pk test and the pre-test EVA simulation familiarization with metabolic gas analysis. During ultrasound imaging and Doppler waveform acquisition, at least 10 cardiac cycles will be monitored and recorded in each of three conditions in sequential order: rest, flexing/bending of the arms and legs, and rest. Compliance of the subjects with the prescribed procedures should be documented, including the time at each station, work rates (cadence and load), symptoms reported by the subjects, and test operator observations.
A standardized set of measurements will be used to monitor and document test subjects during the prebreathe, decompression, and recompression. Test operators will record all symptoms reported by the test subjects throughout the duration of the protocol, whether in response to prompting by the test operators or spontaneous self-reporting. Subjects will be removed from the chamber and repressurized (airlock or chamber) at the onset of DCS (Type I or Type II). NASA defines DCS severity with the following criteria: Mild DCS (Type I), Uncomplicated: Symptoms involving joint pain, peripheral nervous system, or simple skin bends that resolve upon repress or within the first 20 minutes of treatment. Mild DCS (Type I), Complicated: Symptoms involving joint pain, peripheral nervous system, or simple skin bends that DO NOT resolve upon repress or within the first 20 minutes of treatment. Mild DCS (Type I) - Repetitive: Mild DCS symptoms involving joint pain, peripheral nervous system, or simple skin bends that occur after a successful treatment and within 30 days of a prior case of DCS for ground-based exposure. These are considered discrete occurrences of DCS in response to chronologically discrete exposures. Serious DCS (Type II): Symptoms involving the Central Nervous System (CNS), cardiovascular system (circulatory collapse/shock), pulmonary system (chokes).
Test operators will query subjects for responses to standardized questionnaires during each rotation through the resting/ultrasound station. Subjects will report a rating of perceived exertion (RPE) and pain using NASA-defined scales at the end of each exercise bout (i.e., after 5 minutes of arm ergometry, stepping).
2-D imaging and Doppler ultrasound for detection of venous gas emboli will be performed by a qualified test operator during each rotation through the resting/ultrasound station while the subject is at rest and following exercise. Doppler and 2-D ultrasound will be recorded and stored electronically with relevant metadata (e.g., subject ID) for post-exposure review and analysis. Doppler results will be scored using the Spencer coding convention and ultrasound will be scored using the Eftedal-Brubbak (EB) scale (0-7).
Heart rate will be continuously monitored and recorded from which data can be downloaded and stored electronically for post-exposure analysis. Test operators will be able to observe the current heart rate from the device as needed and will manually record heart rate at the end of each 5-minute rotation through the EVA simulation stations.
Oxygen saturation (SpO2) will be monitored and recorded continuously during the prebreathe, decompression, and recompression using a device from which the data can be downloaded and stored electronically for post-exposure analysis. Test operators must be able to observe the current SpO2 from the device as needed and will manually record SpO2 at the end of each 5-minute rotation through the EVA simulation stations.
At the conclusion of each test day, Duke will deliver electronic records to NASA using a secure, NASA approved method. The data package will include subject metadata, console and/or operator's logs (including chamber event time, prebreathe records, EVA time, EVA station schedule), chamber pressure recordings (demonstrating depress and repress rates as well as sustained chamber pressure), chamber environmental conditions (partial pressures of O2, CO2, and N2, temperature, humidity), questionnaires, medical monitoring logs, heart rate and pulse oximetry records (if recorded), Doppler and ultrasound recordings, in-chamber video of EVA workstations, and DCS case descriptions. Doppler and ultrasound images will be scored by 3 reviewers in a blinded fashion.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Healthy Volunteers | Experimental | Other: Altitude, Drug: 100% OxygenEach participant in this group will be exposed to simulated altitude. |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Non-smokers
- VO2pk >35 ml/kg/min (males)
- VO2pk >30 ml/kg/min (females)
Key exclusion criteria (6 listed)
- Pregnancy
- Lung and heart disease
- Hypertension
- Diabetes
- Musculoskeletal pain conditions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AltitudeSubjects will be exposed to simulated altitude (30,000 ft, 4.3 psia) in a hypobaric chamber. This is the same ambient pressure to which astronauts are exposed during EVA ("space walks"). | Other | Healthy Volunteers |
| 100% OxygenOxygen pre-breathing prior to altitude or simulated high altitude exposure is routinely used by the Air Force, NASA and organizations such as Duke Medical Center to prevent and treat decompression sickness as well as for treatment of patients. Oxygen used for this study is medical grade. | Drug | Healthy Volunteers |
Primary outcome
Number of participants with each type of decompression sickness
Time frame: 24 hours
Mild DCS (Type I), Uncomplicated: Symptoms involving joint pain, peripheral nervous system, or simple skin bends that resolve upon repress or within the first 20 minutes of treatment. Mild DCS (Type I), Complicated: Symptoms involving joint pain, peripheral nervous system, or simple skin bends that DO NOT resolve upon repress or within the first 20 minutes of treatment. Mild DCS (Type I) - Repetitive: Mild DCS symptoms involving joint pain, peripheral nervous system, or simple skin bends that occur after a successful treatment and within 30 days of a prior case of DCS for ground-based exposure. These are considered discrete occurrences of DCS in response to chronologically discrete exposures. Serious DCS (Type II): Symptoms involving the Central Nervous System (CNS), cardiovascular system (circulatory collapse/shock), pulmonary system (chokes).
1 secondary outcome
Number of participants with venous gas embolism
Time frame: 24 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jun 2026.
- Background: PubMed 27044459Mollerlokken A, Blogg SL, Doolette DJ, Nishi RY, Pollock NW. Consensus guidelines for the use of ultrasound for diving research. Diving Hyperb Med. 2016 Mar;46(1):26-32.
- Background: PubMed 33648035Le DQ, Dayton PA, Tillmans F, Freiberger JJ, Moon RE, Denoble P, Papadopoulou V. Ultrasound in decompression research: fundamentals, considerations, and future technologies. Undersea Hyperb Med. 2021 First Quarter;48(1):59-72. doi: 10.22462/01.03.2021.8.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Decompression Sickness
Recruiting
NASA Exercise Prebreathe Study
Decompression Sickness
Not yet recruitingObservational study
Health, Fitness, and Safety Knowledge as Determinants of Adverse Events in Recreational Divers in Poland
Decompression Sickness, Barotrauma
Not yet recruitingObservational study
Prediction & Mechanisms of Recovery Following IEDS
Decompression Sickness
Recruiting
Impact of Hyperoxia and Involvement of the Immune System in Diving Accident
Decompression Sickness
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Richard E Moon, MD principal investigator
Duke University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Altitude and 100% Oxygen in people with Decompression Sickness, run by Duke University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants with each type of decompression sickness (time frame: 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06740305, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jun 2026; AzTrials last refreshed its copy on 27 Oct 2026.